SEC Form 4 · accession 0001225208-17-002269
BOSTON SCIENTIFIC CORP · BSX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ian T Meredith
Officer — EVP/ Global Chief Medical Offi
Period of report
Feb 1, 2017
Accepted (ET)
Feb 2, 2017 · 4:58 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000885725
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Deferred Stock UnitsF1,F2 | — | Feb 1, 2017 | A | 15,651 | A | — | Feb 1, 2022 | Common Stock | 15,651 | 15,651 | D |
| Stock Option (Right to Buy)F3 | $23.96 | Feb 1, 2017 | A | 14,450 | A | — | Feb 1, 2027 | Common Stock | 14,450 | 14,450 | D |
Explanation of responses
- F1Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
- F2Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 1, 2018, the first anniversary of the date of grant.
- F3Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 1, 2018, the first anniversary of the date of grant.